Sertraline Hydrochloride

Concomitant use of MAOI isocarboxazid with sertraline hydrochloride increases risk of serotonin syndrome.

Concomitant use of MAOI linezolid with sertraline hydrochloride increases risk of serotonin syndrome.

Concomitant use of intravenous methylene blue with sertraline hydrochloride increases risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome. Sertraline HCl Capsules is contraindicated in patients taking MAOIs.

Concomitant use of MAOI phenelzine with sertraline hydrochloride increases risk of serotonin syndrome.

Concomitant use increases pimozide plasma concentrations, increasing risk of QTc prolongation and ventricular arrhythmias.

Concomitant use of MAOI selegiline with sertraline hydrochloride increases risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome.

Concomitant use of MAOI tranylcypromine with sertraline hydrochloride increases risk of serotonin syndrome.

Concurrent use may potentiate risk of bleeding.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concurrent use may potentiate risk of bleeding.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concurrent use may potentiate risk of bleeding.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concomitant use increases the risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms, particularly during treatment initiation and dosage increases.

Concurrent use may potentiate bleeding risk and increase warfarin plasma concentrations.

Concurrent use may potentiate the risk of bleeding.

Tricyclic antidepressant that increases risk of serotonin syndrome. Monitor for signs and symptoms during treatment initiation and dosage increases.

Cimetidine increases sertraline AUC by 50%, Cmax by 24%, and half-life by 26%. Clinical significance unknown.

Sertraline decreases diazepam clearance by 32% and increases desmethyldiazepam Tmax by 23%. Clinical significance unknown.

Potential shift in plasma concentrations due to sertraline's tight plasma protein binding, potentially resulting in adverse effects.

Other SSRIs increase risk of serotonin syndrome; monitor for signs and symptoms.

Opioid that increases risk of serotonin syndrome. Monitor for signs and symptoms during treatment initiation and dosage increases.

Concurrent use may potentiate the risk of bleeding.

Other SSRIs increase risk of serotonin syndrome; monitor for signs and symptoms.

Triptan that increases risk of serotonin syndrome. Monitor for signs and symptoms during treatment initiation and dosage increases.

SNRIs increase risk of serotonin syndrome; monitor for signs and symptoms.

Atenolol – Sertraline hydrochloride (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.

There was a 23% increase in T max for desmethyldiazepam in the sertraline hydrochloride group compared to a 20% decrease in the placebo group (p<0.03).

Examples: Specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).

Examples: Specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).

Examples: propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, thioridazine, tolterodine, venlafaxine Phenytoin Clinical Impact: Phenytoin is a narrow therapeutic index drug.

Examples: Specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).

Examples: propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, thioridazine, tolterodine, venlafaxine Phenytoin Clinical Impact: Phenytoin is a narrow therapeutic index drug.

Examples: Specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).

Examples: Specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).

Hypoglycemic Drugs –In a placebo-controlled trial in normal volunteers, administration of sertraline hydrochloride for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline hydrochloride administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.